Wednesday, April 24, 2024 5:22:43 PM
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mentioned: NKGN
GlobeNewswireApril 24, 2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31-June 4, 2024.
ePublication Details:
Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
Authors: Victoria Chua, Sant Chawla, Erlinda Gordon, William Feske, Lucia Hui, Hank Lee, Yoonmi Kang, Juan Mata, Katia Betito, Paul Chang, Paul Song
Abstract Number: e14515
Session Type: Publication Only
Session Title: Developmental Therapeutics - Immunotherapy
A copy of the ePublication will be available on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/.
Recent NKGN News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:00:10 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/22/2024 09:22:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 08:42:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:05:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:06:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:19:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:16:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:14:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:11:45 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 06:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 11:12:43 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:19:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:14:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:01:25 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/19/2023 06:41:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:39:00 PM
- NKGen Biotech Shares Rise 8% After FDA Clears IND Application for SNK01 • Dow Jones News • 10/24/2023 02:56:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 12:05:14 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM